How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Access detailed historical stock prices, including daily closing prices, for RXRX. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...